This trial studies how well radiation therapy techniques, volumetric modulated arc therapy (VMAT) and tomotherapy, work to reduce doses to the lung compared to standard total body irradiation methods to prevent pulmonary toxicities. Standard total body irradiation is limited in its ability to spare normal organs, with only the lung being partially spared by lung blocks and risks the development of pulmonary toxicities. Reducing the doses to the lung using VMAT or tomotherapy may improve survival and decrease long term lung side effects in patients undergoing stem cell transplant.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04281199.
PRIMARY OBJECTIVES:
I. To test whether we can achieve a mean lung dose of < 8 Gy and still treat minimum 85% of the total body to the prescribed dose in patients undergoing allogeneic hematopoietic stem cell transplantation who are eligible for standard total body irradiation (TBI)-based myeloablative regimens.
II. To evaluate TBI coverage from tomotherapy and VMAT with new lung sparing guidelines.
III. To assess the rate of adverse events with intensity-modulated radiation therapy (IMRT) TBI: type, frequency, severity, attribution, time course, duration, and complications (acute graft versus host disease [GvHD], infections, and delayed neutrophil/platelet engraftment) measured by Bearman and Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.
SECONDARY OBJECTIVES:
I. To evaluate dose homogeneity for all target and non-target structures using dose volume histograms.
II. To evaluate non-relapse mortality at 100 days, and 1 year post IMRT TBI.
III. To evaluate relapse-free survival (RFS) at 100 days, and 1 year post IMRT TBI.
IV. To evaluate extramedullary recurrence rate at 1 year post IMRT TBI.
OUTLINE:
Patients undergo TBI using IMRT with VMAT or tomotherapy, then undergo stem cell transplantation while on study.
After completion of study treatment, patients are followed up at 100 days and 1 year post transplant.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationCity of Hope Comprehensive Cancer Center
Principal InvestigatorSavita Visalakshi Dandapani
